Form 4: United Therapeutics Exec Sells Shares via 10b5-1 Plan

United Therapeutics Corp. reports that EVP & General Counsel Paul A. Mahon executed a pre-arranged 10b5-1 plan, involving the exercise of stock options and sale of common stock.

Summary

• Paul A. Mahon, EVP & General Counsel of United Therapeutics Corporation, reported transactions on May 21, 2026.
• These transactions involved the exercise of stock options and the subsequent sale of common stock.
• The exercise of stock options occurred at a price of $146.03 per share, resulting in the acquisition of 8,300 shares.
• Following the exercise, a total of 11,300 shares were sold in various transactions at weighted average prices ranging from $555.56 to $566.25.
• These sales were conducted under a Rule 10b5-1 trading plan established on August 11, 2025, designed to satisfy affirmative defense conditions.
• Mahon's direct beneficial ownership of United Therapeutics Corp. common stock changed from an initial amount to 45,172 shares after these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves a significant sale of shares by an executive, the use of a 10b5-1 plan mitigates concerns about insider knowledge and suggests a planned financial strategy.

Positives

• The transactions were executed under a pre-arranged 10b5-1 plan, indicating structured and planned financial activity rather than opportunistic trading.
• The exercise of stock options at a lower price ($146.03) and sale at significantly higher prices (weighted average around $555-$566) suggests a profitable execution of the plan.

Negatives

• A significant number of shares (11,300 in total, including the 8,300 from option exercise) were sold by a key executive, which could be perceived negatively by the market.
• The sale of shares at prices significantly higher than the option exercise price, while profitable for the executive, represents a divestment of equity.

Risks

• The filing does not explicitly mention any new risks or challenges.
• However, the sale of a substantial number of shares by a high-ranking executive could be interpreted by the market as a lack of confidence, though the 10b5-1 plan mitigates this interpretation.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future company performance. It solely reports past transactions by an executive.

Management Comments

• The transactions were made pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for transactions executed in multiple trades at weighted average prices.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by United Therapeutics Corp. executive Paul A. Mahon is a common practice for executives to diversify holdings or manage personal finances while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders: May observe the sale of shares by an executive, but the 10b5-1 plan context suggests it's a pre-planned financial action rather than a signal of negative company outlook.
• Employees: The transaction does not directly impact employee stock options or benefits.
• Creditors/Suppliers: No direct impact is indicated by this filing.

Next Steps

• No specific next steps are outlined in this filing beyond the completion of the reported transactions.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Insider Trading, Stock Options, 10b5-1 Plan, Share Sale, Paul A. Mahon, Beneficial Ownership